Gastric Cancer
Cross-source consensus on Gastric Cancer from 1 sources and 5 claims.
1 sources · 5 claims
Uses
Benefits
Risks & contraindications
Other
Highlighted claims
- Gastric cancer is one of the most prevalent and deadly cancers globally, with over one million new diagnoses annually and incidence and mortality rates ranking in the global top five. — CapeOX (capecitabine and oxaliplatin) combined with sintilimab and bevacizumab biosimilar (IBI305) for first-line treatment of advanced gastric or oesophagogastric junction adenocarcinoma: study protocol for a single-arm, phase Ib/II trial
- The large majority of gastric cancer patients are HER2-negative and therefore ineligible for trastuzumab. — CapeOX (capecitabine and oxaliplatin) combined with sintilimab and bevacizumab biosimilar (IBI305) for first-line treatment of advanced gastric or oesophagogastric junction adenocarcinoma: study protocol for a single-arm, phase Ib/II trial
- Despite advances in chemotherapy, first-line treatment for advanced G/GEJ adenocarcinoma yields a median overall survival of approximately one year. — CapeOX (capecitabine and oxaliplatin) combined with sintilimab and bevacizumab biosimilar (IBI305) for first-line treatment of advanced gastric or oesophagogastric junction adenocarcinoma: study protocol for a single-arm, phase Ib/II trial
- HER2-positive disease, the only subgroup eligible for trastuzumab, affects only 7.1% to 12.1% of the general gastric cancer population. — CapeOX (capecitabine and oxaliplatin) combined with sintilimab and bevacizumab biosimilar (IBI305) for first-line treatment of advanced gastric or oesophagogastric junction adenocarcinoma: study protocol for a single-arm, phase Ib/II trial
- The inability to benefit from either HER2-targeted or PD-1-based immunotherapy in a large proportion of gastric cancer patients creates the rationale for adding anti-angiogenic therapy to broaden immune responsiveness. — CapeOX (capecitabine and oxaliplatin) combined with sintilimab and bevacizumab biosimilar (IBI305) for first-line treatment of advanced gastric or oesophagogastric junction adenocarcinoma: study protocol for a single-arm, phase Ib/II trial